Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Non-invasive Aesthetic Treatment Market, By Procedure
7.1. Non-invasive Aesthetic Treatment Market, By Procedure Type, 2020-2030
7.1.1. Injectables
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Skin Rejuvenation
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Others
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Non-invasive Aesthetic Treatment Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.2. Europe
8.2.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.3. APAC
8.3.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.4. MEA
8.4.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.5. Latin America
8.5.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, By Procedure (2016-2030)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, By Procedure (2016-2030)
Chapter 9. Company Profiles
9.1. Hologic, Inc.
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Allergan, Inc.
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Galderma S.A
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Alma Lasers.
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Syneron Candela.
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Johnson & Johnson
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Merz Pharma
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. Lumenis
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. Solta Medical
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
9.10. Cutera, Inc.
9.10.1. Company Overview
9.10.2. Product Offerings
9.10.3. Financial Performance
9.10.4. Recent Initiatives
9.11. Revance Therapeutics, Inc.
9.11.1. Company Overview
9.11.2. Product Offerings
9.11.3. Financial Performance
9.11.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
Glossary of Terms